In the past week, there was an increase of 1.1 million shares! Director's heavy increase sends a positive signal, CSTONE PHARMA-B(02616) opens up long-term growth opportunities.

Innovative drug company CSTONE PHARMA-B (02616) has recently received support from multiple directors. Since June, Dr. Yang Jianxin, Executive Director and Chief Executive Officer (CEO), has purchased a total of 650,000 shares of the company in 4 separate transactions; Li Wei, Chairman of the Board and Non-Executive Director, and Non-Executive Director Hitchner III Kenneth Walton have also purchased 50,000 and 400,000 shares respectively. Several directors have collectively purchased 1.1 million shares in the past week, totaling approximately 4.95 million Hong Kong dollars, which not only reflects a rational assessment of the company's asset value, but also serves as a strong endorsement of the company's future development value. Since becoming CEO in August 2022, Dr. Yang has accumulated 13.13 million shares through personal investments. Dr. Yang previously stated that the share acquisition plan demonstrates the board of directors' and senior management's firm confidence in the global competitiveness of the company's product pipeline. The current trading price does not reflect the actual value of the company's research and development achievements. "We will continue to accelerate key clinical projects, including disclosing multiple important clinical progress of CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibodies), initiating global multi-center Phase III registration trials for CS2009, and continuing to create value for patients and shareholders." It is worth noting that CSTONE PHARMA's clinical progress and business development potential have also been highly regarded by institutions. Jefferies released a research report stating that the company's core asset CS2009 product has outstanding differentiation advantages, potential for overall survival benefit, and a wide range of business development opportunities; Goldman Sachs believes that the Phase I/II data of CS2009 is positive and reiterated their positive view on the overall drug characteristics exhibited by CS2009. Overall, with the intensification of executive share acquisitions, continually impressive clinical trial data, and steady progress in the innovative pipeline, CSTONE PHARMA is expected to further release growth expectations, creating long-term value for investors.